Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
92 hedge funds and large institutions have $122M invested in Unity Biotechnology in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 27 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
35% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $761K
11% more capital invested
Capital invested by funds: $109M → $122M (+$12.3M)
8% more funds holding
Funds holding: 85 → 92 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.24% less ownership
Funds ownership: 3.95% → 3.71% (-0.24%)
26% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.23M |
| 2 |
Two Sigma Investments
New York
|
+$827K |
| 3 |
Axa
Paris,
France
|
+$806K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$592K |
| 5 |
Two Sigma Advisers
New York
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.19M |
| 2 |
Morgan Stanley
New York
|
-$1.56M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$865K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$544K |
| 5 |
Jane Street
New York
|
-$539K |
UBX Hedge Fund Activity: Q1 2021 in Review
92 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2021, worth a combined $122M — up 11% from $109M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new UBX positions and 10 closed out — a net gain of 7 holders — while 20 added to existing stakes and 27 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $1.23M. The largest seller was Fidelity Investments, cutting an estimated $3.19M.
- 92 institutional investors held Unity Biotechnology (UBX) as of Q1 2021, up from 85 in Q4 2020.
- Funds reported $122M of Unity Biotechnology stock for Q1 2021, up 11% quarter-over-quarter.
- 17 funds opened new Unity Biotechnology positions in Q1 2021 and 10 closed out, a net change of +7 holders.
- The largest Unity Biotechnology buyer in Q1 2021 was Jacobs Levy Equity Management, an estimated $1.23M added.
- The largest Unity Biotechnology seller in Q1 2021 was Fidelity Investments, an estimated $3.19M sold.
Based on aggregated 13F filings for Q1 2021.